Taro Pharmaceutical Industries Ltd. (TARO)
| Market Cap | 1.26B |
| Revenue (ttm) | 570.90M |
| Net Income (ttm) | 91.11M |
| Shares Out | 37.58M |
| EPS (ttm) | 2.48 |
| PE Ratio | 13.52 |
| Forward PE | 9.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,269 |
| Open | 34.00 |
| Previous Close | 32.76 |
| Day's Range | 33.03 - 34.00 |
| 52-Week Range | 32.15 - 72.97 |
| Beta | 0.74 |
| Analysts | Buy |
| Price Target | 55.08 (+64.2%) |
| Earnings Date | Jul 26, 2022 |
About TARO
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprising allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer,... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TARO stock is "Buy." The 12-month stock price forecast is 55.08, which is an increase of 64.22% from the latest price.
News
Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial ...
BRAMPTON, Ontario--(BUSINESS WIRE)--TARO PHARMACEUTICALS INC. ISSUES VOLUNTARY TYPE I RECALL OF TARO-ZOLEDRONIC ACID INJECTION, 5 MG/100 ML, 100 ML VIAL
Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates
Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Taro Provides Results for the Quarter Ended June 30, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2022
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--07-26-22 March 2022 Annual Report on Form 20-F
Taro to Release First Quarter Results on July 27, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the clo...
Taro Provides Results for the Year Ended March 31, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE YEAR ENDED MARCH 31, 2022
Taro to Announce Full Year Results on May 26, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 27, 2022
Taro Completes Acquisition of Alchemee
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Completes Acquisition of Alchemee
Taro to Acquire Alchemee From Galderma
ZUG, Switzerland & HAWTHORNE, N.Y.--(BUSINESS WIRE)--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Al...
Taro Pharmaceutical (TARO) Q3 Earnings and Revenues Miss Estimates
Taro (TARO) delivered earnings and revenue surprises of -23.08% and 2.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Taro Provides Results for December 31, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR DECEMBER 31, 2021
Taro to Announce Third Quarter Results on January 27, 2022
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Third Quarter Results on January 27, 2022
Taro Pharmaceutical (TARO) Earnings Expected to Grow: Should You Buy?
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro (TARO) Surges 6.6%: Is This an Indication of Further Gains?
Taro (TARO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Taro Appoints New Chief Financial Officer
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO APPOINTS NEW CHIEF FINANCIAL OFFICER
Taro Pharmaceutical (TARO) Lags Q2 Earnings and Revenue Estimates
Taro (TARO) delivered earnings and revenue surprises of -35.29% and -13.86%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Taro Provides Results for September 30, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR SEPTEMBER 30, 2021
Taro to Announce Second Quarter Results on October 28, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE SECOND QUARTER RESULTS ON OCTOBER 28, 2021
Earnings Preview: Taro Pharmaceutical (TARO) Q2 Earnings Expected to Decline
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates
Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Taro Provides Results for Quarter Ended June 30, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR QUARTER ENDED JUNE 30, 2021
Taro to Announce First Quarter Results on July 27, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO ANNOUNCE FIRST QUARTER RESULTS ON JULY 27, 2021
Taro Pharma (TARO) Sees Hammer Chart Pattern: Time to Buy?
Taro Pharmaceutical Industries (TARO) has been struggling lately, but the selling pressure may be coming to an end soon.
Taro Announces Resignation of Chief Financial Officer
HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO ANNOUNCES RESIGNATION OF CHIEF FINANCIAL OFFICER
Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Annual Report on Form 20-F Available for Fiscal Year Ended March 31, 2021